In the battle against Covid-19, a vaccine is essential. Today, it seems, we may have finally found a good candidate. A vaccine developed by Pfizer and BioNTech appears to prevent more than 90% of infections, the same reports Pfizer .
“Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine study provides initial evidence of our vaccine's ability to prevent COVID-19, ”says Dr. Albert Bourla, president and CEO of Pfizer.
The results were obtained from an interim analysis that took place after 94 participants, separated between those who received a placebo and those who were vaccinated, they contracted the virus. However, the study will not be completed until at least 164 cases have been verified and evaluated.
Pfizer vaccine for Covid-19: better than expected, but curb enthusiasm
The news is extremely promising, due to this 90% effectiveness. The effectiveness of the first vaccines was expected to be in a much lower range, from 60% to 70%. “The first interim analysis of our global Phase 3 study provides evidence that a vaccine can effectively prevent COVID-19. This is a win for innovation, science and a global collaborative effort, ”echoes Pfizer prof. Ugur Sahin, co-founder and CEO of BioNTech.
However, for now, many details about the vaccine's effectiveness are missing, such as how it works in subgroups and whether it prevents serious complications. The analyzes that might provide that data have yet to be conducted.
The good news is that the study's data monitoring committee has not yet identified any serious safety concerns. For now, Pfizer has to get it two months of safety follow-up data to obtain an emergency clearance from US regulatory authorities.
If all goes well with that data, Pfizer could file an authorization application in the United States this month. We hope the vaccine is the beginning of the end of a pandemic that has already killed more than 1,2 million people around the world.